Moderna Just Dropped 17% in a Week as 2027 Cash Costs Head to $4 Billion. Time to Sell, or Load Up?

Rexielyn Diaz • 4 minute read
Reviewed by: David Hanson
Last updated Nov 19, 2026

nuttapong punna's Images and piktochart via Canva 

Key Takeaways

  • Moderna stock fell 17% in the past week after guiding to about $4 billion of cash costs in 2027 and up to $4.5 billion a year through 2030.
  • Most of that spending goes to cancer drugs led by intismeran, Moderna’s melanoma vaccine with Merck, raising the bar for BioNTech, whose revenue is shrinking.
  • Analysts’ 2028 revenue estimate is below one year of those costs, and the stock trades at more than four times its usual sales multiple.

Moderna (MRNA) is down 17% in the past week as investors priced in a costlier push behind intismeran, the melanoma vaccine it shares with Merck (MRK). That also raises the stakes for BioNTech (BNTX), which has mRNA cancer drugs in its own late-stage pipeline.

The cancer bet comes with a bigger bill

At its Analyst Day before the Nov. 12 open, Moderna guided to about $4 billion of cash costs in 2027 and $4 billion to $4.5 billion a year through 2030. A year earlier, it had put 2027 costs at $3.5 billion to $3.9 billion. Analysts expect revenue to nearly double from 2025 to 2028:

Bar chart from TIKR of Moderna's revenue, actual and consensus estimates, $ billions, fiscal 2024-2029.
Moderna (MRNA): revenue, actual and consensus estimates, $ billions, fiscal 2024-2029 (TIKR)

But 2028’s $3.72 billion still falls short of $4 billion in costs. Roughly $9 billion of cash, investments and undrawn credit at the end of 2026 covers the gap for now.

TIKR tracks 23 analysts on Moderna. How many say “Buy”?

See the full breakdown of Buy, Hold, and Sell ratings on Moderna, along with Wall Street’s revenue and earnings estimates, all in one place. More than 500,000 investors use TIKR to research stocks like this one. See Moderna’s Analyst Ratings

Merck can afford the bet, BioNTech less so

Merck splits intismeran’s costs and profits evenly with Moderna. Still, the bill matters far less to Merck, whose Keytruda sold $8.6 billion in the third quarter alone. BioNTech agreed on Nov. 10 to buy a $205 million FDA priority review voucher for a future cancer filing. However, analysts expect its revenue to fall 35.4% this year. Can it keep up with a rival budgeting $4 billion a year?

Still pricey ahead of the filing

Moderna trades at about 37x forward sales, against a five-year average of 8x:

Line chart from TIKR of Moderna's forward (NTM) price/sales, last 5 years.
Moderna (MRNA): forward (NTM) price/sales, last 5 years (TIKR)

The consensus target has climbed to $165, which is still below the share price:

Line chart from TIKR of Moderna's analysts' consensus (mean) price target, $ per share, last year.
Moderna (MRNA): analysts’ consensus (mean) price target, $ per share, last year (TIKR)

Moderna CEO Stéphane Bancel told Mad Money on Nov. 12 that “we are working very, very deliberately to try to get the filing to the FDA before the end of the year.” Its 2027 guidance should come with the fourth-quarter report in February.

I wouldn’t load up at 37x sales. Investors have already paid for a launch that hasn’t been filed yet, and getting there just got pricier. Of course, a 2027 revenue outlook well above the Street’s $2.69 billion would make $4 billion of yearly costs far easier to carry.

So what is Moderna stock actually worth?

TIKR lets you forecast the future price of any stock in less than a minute. Just enter a few assumptions into TIKR’s valuation model and see what Moderna could be worth. Start from Wall Street consensus estimates, or adjust the inputs to reflect your own view of the business. It’s free to use.

Value Moderna for free

Disclaimer:

Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any of the stocks mentioned. Thank you for reading, and happy investing!

Join thousands of investors worldwide who use TIKR to supercharge their investment analysis.

Sign Up for FREENo credit card required